NVAX
Novavax, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.22
−1.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 413.8M | 1.1B | 682.2M | 556.4M | 1.6B |
| Cost of Revenue | 91.6M | 71.1M | 202.7M | 343.8M | 902.6M |
| Gross Profit | 322.2M | 1.1B | 479.4M | 212.6M | 696.3M |
| Operating Expenses | |||||
| R&D Expense | 338.4M | 336.8M | 391.2M | 737.5M | 1.2B |
| SG&A Expense | 87.4M | 150.3M | 337.2M | 468.9M | 488.7M |
| General & Admin Expense | — | — | — | — | 488.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 123.7M | 1.9M | — | (427.3M) | (382.9M) |
| Total Operating Expenses | 549.5M | 489.1M | 728.4M | 779.1M | 1.3B |
| Cost and Expenses | 641.1M | 560.2M | 931.1M | 1.1B | 2.2B |
| Operating Income (EBIT) | (227.3M) | 563.3M | (248.9M) | (566.5M) | (644.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 12.1M | 22.5M | 20.1M | 14.4M | 19.9M |
| Net Interest Income | (12.1M) | (22.5M) | (20.1M) | (14.4M) | (19.9M) |
| Other Non-Op Income/Expense | (18.0M) | (121.1M) | 72.3M | 23.5M | (8.9M) |
| Non-Operating Income (excl Interest) | (3.9M) | 98.6M | (92.4M) | (37.9M) | (11.0M) |
| EBT (Pre-Tax Income) | (245.3M) | 442.2M | (176.6M) | (543.0M) | (653.6M) |
| Income Tax Expense | 2.4M | 1.9M | 10.9M | 2.0M | 4.3M |
| Bottom Line | |||||
| Net Income | (247.7M) | 440.3M | (187.5M) | (545.1M) | (657.9M) |
| Earnings from Cont. Ops | (247.7M) | 440.3M | (187.5M) | (545.1M) | (657.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (247.7M) | 440.3M | (187.5M) | (545.1M) | (657.9M) |
| Per Share | |||||
| Basic EPS | ($1.52) | $2.72 | ($1.23) | ($5.41) | ($8.42) |
| Diluted EPS | ($1.52) | $2.54 | ($1.23) | ($5.41) | ($8.42) |
| Revenue Per Share | $2.51 | $6.94 | $4.48 | $5.52 | $20.45 |
| Shares | |||||
| Basic Shares Outstanding | 164.6M | 162.0M | 152.2M | 100.8M | 78.2M |
| Diluted Shares Outstanding | 164.6M | 173.1M | 152.2M | 100.8M | 78.2M |
| Profitability Metrics | |||||
| EBITDA | (202.5M) | 492.3M | (108.0M) | (487.4M) | (604.7M) |
| D&A | 20.9M | 27.6M | 48.5M | 41.2M | 29.1M |
| EBIT | (223.4M) | 464.7M | (156.5M) | (528.6M) | (633.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026